Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

Vaccine

Volumn 19, Issue 13-14, 2001, Pages 1820-1826

  Harrison, Christopher J ^a   Miller, Richard L ^b   Bernstein, David I ^c  

^a CREIGHTON UNIVERSITY   (United States)

^b 3M COMPANY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Herpes vaccine; Imiquimod; Recurrent HSV

Indexed keywords

ANTIBODY; CYTOKINE; GLYCOPROTEIN; HERPES VACCINE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 2; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT PAD; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT INFECTION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; INJECTIONS, SUBCUTANEOUS; INTERFERON INDUCERS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; VIRAL ENVELOPE PROTEINS;

EID: 0035825571     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00387-X     Document Type: Article

References (29)

1. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time
2. Treatment of first episode genital HSV with oral acyclovir: Long term follow-up of recurrences: A preliminary report
3. Suppression of recurrent genital herpes with oral acyclovir
4. Cidofovir use in acyclovir-resistant herpes infection
5. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: Preliminary results of a controlled, randomized, regimen-comparative trial
6. New antiherpesvirus agents. Their targets and therapeutic potential
7. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections
8. Herpes simplex virus vaccines
9. Herpesvirus vaccines. Development, controversies, and applications
10. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development
11. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs
12. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
13. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections
14. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs
15. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs
16. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod
17. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy
18. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: Effects of acyclovir
19. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
20. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs
21. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: Factors influencing efficacy
22. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs
23. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine
24. Herpes simplex virus glycoprotein treatment of recurrent genital herpes
25. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex type 2 in guinea pigs
26. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%
27. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod
28. Low doses of interferon alpha result in more effective clinical natural killer cell activation
29. A species of human alpha interferon that lacks the ability to boost human natural killer activity